Methamphetamine Abuse Research Center

甲基苯丙胺滥用研究中心

• 批准号: 7657312
• 负责人: Aaron J. Janowsky
• 金额: $ 95.62万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7657312
• 关键词: Methamphetamine; Abuse; Research; Center

DESCRIPTION (provided by applicant): Oregon is one of a few states where methamphetamine (MA) abusers without a greater history of cocaine abuse are recruited for clinical research. The Methamphetamine Abuse Research Center (MARC) will characterize effects of MA administration and withdrawal at molecular, neurochemical, anatomical, behavioral, and clinical levels, to identify obstacles to recovery in MA abusers. Overarching themes addressed in preclinical and clinical research components using common methodologies include neuroadaptation to MA, neuroanatomy of MA-related behaviors, stressor responsivity, and impulsivity. Human and animal protocols inform one another with respect to these themes, forming the basis for bidirectional translational research. The Center's Administrative Core facilitates interactions among MARC investigators, and the Biostatistics Core analyzes associations and correlations within and across components. The Animal Core breeds and maintains genetically selected lines and other strains, and provides them to MARC investigators. The Education Core coordinates the research training of M.D. and Ph.D. pre- and postdoctoral fellows, and organizes and disseminates both clinical and preclinical information from MARC investigators to Centers and Oregon's rural areas that are impacted by MA production and abuse. Scientific Component 5 correlates acetylcholine release with active and passive administration of MA and provides neuroanatomic and molecular signaling data relevant to MA seeking for use in other components. Scientific Component 6, examines genetic influences, and behavioral and neurochemical correlates (in collaboration with Component 5) in mice selected for differences in MA-induced neuroadaptation and MA self-administration. Nomination of genetic candidates from this preclinical work could inform treatment strategies in clinical Component 7, and specific genetic associations can be pursued in patients from clinical components. Scientific Component 7 evaluates the relationship between symptom severity at intake and treatment failure in inpatients, tests (3-receptor and cholinergic medications, and conducts human laboratory evaluations of stressor responsivity. Component 8, the Pilot Projects, provides a means to support the development of multiple new directions in research on MA abuse. Thus, the MARC's themes address clinically relevant issues using innovative multidisciplinary approaches.

描述（由申请人提供）： 俄勒冈州是招募没有更多可卡因滥用史的甲基苯丙胺 (MA) 滥用者进行临床研究的少数州之一。甲基苯丙胺滥用研究中心 (MARC) 将在分子、神经化学、解剖、行为和临床水平上表征甲基苯丙胺给药和戒断的影响，以确定甲基苯丙胺滥用者康复的障碍。使用通用方法的临床前和临床研究部分涉及的总体主题包括 MA 的神经适应、MA 相关行为的神经解剖学、压力源反应性和冲动性。人类和动物协议在这些主题方面相互告知，形成双向转化研究的基础。该中心的管理核心促进 MARC 研究人员之间的互动，生物统计核心分析各组成部分内部和之间的关联和相关性。动物核心培育和维持基因选择的品系和其他品系，并将其提供给 MARC 研究人员。教育核心协调医学博士和博士的研究培训。博士前和博士后研究员，并将 MARC 研究人员的临床和临床前信息组织和传播到受 MA 生产和滥用影响的中心和俄勒冈州农村地区。科学组件 5 将乙酰胆碱释放与 MA 的主动和被动给药相关联，并提供与寻求在其他组件中使用的 MA 相关的神经解剖学和分子信号传导数据。科学部分 6，检查因 MA 诱导的神经适应和 MA 自我给药差异而选择的小鼠的遗传影响以及行为和神经化学相关性（与部分 5 合作）。从这项临床前工作中提名的候选基因可以为临床第 7 部分的治疗策略提供信息，并且可以从临床部分的患者中寻找特定的遗传关联。科学组成部分 7 评估住院患者服用时症状严重程度与治疗失败之间的关系、测试（3-受体和胆碱能药物），并对压力源反应性进行人体实验室评估。组成部分 8，试点项目，提供了支持开发MA 滥用研究的多个新方向 因此，MARC 的主题利用创新的多学科方法解决临床相关问题。